Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease

PHASE2TerminatedINTERVENTIONAL
Enrollment

246

Participants

Timeline

Start Date

November 30, 2007

Primary Completion Date

April 30, 2010

Conditions
Crohn's Disease
Interventions
BIOLOGICAL

Placebo

every 4 weeks, IV

BIOLOGICAL

ABT-874

400 mg IV every 4 weeks

BIOLOGICAL

ABT-874

700 mg IV every 4 weeks

Trial Locations (61)

1090

Site Ref # / Investigator 16225, Vienna

2650

Site Ref # / Investigator 16235, Hvivdovre

2820

Site Ref # / Investigator 16230, Bonheiden

3000

Site Ref # / Investigator 16231, Leuven

3128

Site Ref # / Investigator 16983, Box Hill

5000

Site Ref # / Investigator 16234, Odense C

10029

Site Ref # / Investigator 7047, New York

11021

Site Ref # / Investigator 6689, Great Neck

11042

Site Ref # / Investigator 6652, Lake Success

20815

Site Ref # / Investigator 6865, Chevy Chase

21204

Site Ref # / Investigator 10202, Towson

23320

Site Ref # / Investigator 9115, Chesapeake

27612

Site Ref # / Investigator 6651, Raleigh

28207

Site Ref # / Investigator 6785, Charlotte

28655

Site Ref # / Investigator 9070, Morgantown

28801

Site Ref # / Investigator 6693, Asheville

30308

Site Ref # / Investigator 6691, Atlanta

30342

Site Ref # / Investigator 6642, Atlanta

31201

Site Ref # / Investigator 8797, Macon

32256

Site Ref # / Investigator 6794, Jacksonville

32610

Site Ref # / Investigator 6694, Gainesville

32789

Site Ref # / Investigator 6687, Winter Park

33542

Site Ref # / Investigator 6667, Zephyrhills

37203

Site Ref # / Investigator 6648, Nashville

37205

Site Ref # / Investigator 6793, Nashville

38138

Site Ref # / Investigator 7004, Germantown

44122

Site Ref # / Investigator 6665, Beachwood

45219

Site Ref # / Investigator 6690, Cincinnati

55905

Site Ref # / Investigator 6866, Rochester

63110

Site Ref # / Investigator 7048, St Louis

65265

Site Ref # / Investigator 6778, Mexico

70809

Site Ref # / Investigator 6925, Baton Rouge

78681

Site Ref # / Investigator 8357, Round Rock

84405

Site Ref # / Investigator 6688, Ogden

89128

Site Ref # / Investigator 7952, Las Vegas

92123

Site Ref # / Investigator 6643, San Diego

92868

Site Ref # / Investigator 6792, Orange

97220

Site Ref # / Investigator 6786, Portland

98195

Site Ref # / Investigator 6674, Seattle

06518

Site Ref # / Investigator 6670, Hamden

07927

Site Ref # / Investigator 6647, Cedar Knolls

37212-1610

Site Ref # / Investigator 7054, Nashville

T2N 4Z6

Site Ref # / Investigator 9422, Calgary

T6G 2X8

Site Ref # / Investigator 14042, Edmonton

V6Z-2K5

Site Ref # / Investigator 7610, Vancouver

R3A 1R9

Site Ref # / Investigator 8206, Winnipeg

A1B - 3V6

Site Ref # / Investigator 7634, St. John's

B3H 2Y9

Site Ref # / Investigator 7596, Halifax

B2N 1L2

Site Ref # / Investigator 7630, Truro

L8N 3Z5

Site Ref # / Investigator 7641, Hamilton

N6A 5K8

Site Ref # / Investigator 10681, London

M5G 1X5

Site Ref # / Investigator 17901, Toronto

H1T 2M4

Site Ref # / Investigator 7629, Montreal

H3A 1A1

Site Ref # / Investigator 14702, Montreal

H3T 1E2

Site Ref # / Investigator 15061, Montreal

G1R 2J6

Site Ref # / Investigator 17881, Québec

S7K 1N4

Site Ref # / Investigator 7642, Saskatoon

S7N 0W8

Site Ref # / Investigator 14821, Saskatoon

DK-2730

Site Ref # / Investigator 16985, Herlev

00717

Site Ref # / Investigator 10961, Ponce

00935

Site Ref # / Investigator 16801, San Juan

Sponsors

Lead Sponsor

All Listed Sponsors
lead

Abbott

INDUSTRY

NCT00562887 - Dose Ranging Study Comparing the Efficacy, Safety and Pharmacokinetics of Intravenous Infusions of ABT-874 vs Placebo in Subjects With Active Crohn's Disease | Biotech Hunter | Biotech Hunter